TYK2 and venous thromboembolism: Unlike JAK inhibitors, TYK2 inhibitors do not carry the same risk of venous thromboembolism or major adverse cardiovascular events, which informed our decision to pursue this therapy for a patient with a remote history of deep vein thrombosis.